Literature DB >> 21575853

Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study.

F Olivennes1, C M Howies, A Borini, M Germond, G Trew, M Wikland, F Zegers-Hochschild, H Saunders, V Alam.   

Abstract

The CONSORT dosing algorithm individualizes recombinant human FSH (r-hFSH) doses for assisted reproduction technologies, assigning 37.5 IU increments according to patient characteristics: basal FSH, body mass index, age and antral follicle count. A prospective, uncontrolled, international, 18-centre, pilot study of normo-ovulatory women aged 18-34 years inclusive undergoing a long agonist treatment protocol was performed. Follitropin alfa filled-by-mass (GONAL-f®) dose was assigned by the algorithm and was intended to be altered only for risk of ovarian hyperstimulation syndrome (OHSS). Primary end-point was number of oocytes retrieved. Dose groups containing ≥5 patients were analysed: 75 IU (n = 48), 112.5 IU in = 45), 150 IU (n = 34), 187.5 IU (n = 24), 225 IU (n = 10). Cancellations due to inadequate response were higher than expected in the 75 IU group (12/48). Overall, a median of 9.0 oocytes were retrieved (8.5, 8.0, 10.0, 12.0 and 8.0 in the 75, 112.5, 150, 187.5 and 225 IU groups respectively). Clinical pregnancy rates/cycle started were 31.3, 31.1, 35.3, 50.0 and 20.0%, respectively (overall, 34.2%). Two patients had severe OHSS. Use of the CONSORT algorithm achieved an adequate oocyte yield and good pregnancy rates in this preliminary study. Adjustment of the algorithm could reduce cancellation rates.
Copyright © 2011 Reproductive Healthcare Ltd. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Year:  2011        PMID: 21575853     DOI: 10.1016/S1472-6483(11)60012-6

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  7 in total

1.  Gonadotropin dose is negatively correlated with live birth rate: analysis of more than 650,000 assisted reproductive technology cycles.

Authors:  Valerie L Baker; Morton B Brown; Barbara Luke; George W Smith; James J Ireland
Journal:  Fertil Steril       Date:  2015-08-18       Impact factor: 7.329

2.  An in silico model using prognostic genetic factors for ovarian response in controlled ovarian stimulation: A systematic review.

Authors:  B S Eisele; G C Villalba Silva; C Bessow; R Donato; V K Genro; J S Cunha-Filho
Journal:  J Assist Reprod Genet       Date:  2021-03-31       Impact factor: 3.357

Review 3.  Biomarkers in reproductive medicine: the promise, and can it be fulfilled?

Authors:  Stephen S Palmer; Kurt T Barnhart
Journal:  Fertil Steril       Date:  2012-12-14       Impact factor: 7.329

4.  A Novel Nomogram for Individualized Gonadotropin Starting Dose in GnRH Antagonist Protocol.

Authors:  Yubin Li; Yuwei Duan; Xi Yuan; Bing Cai; Yanwen Xu; Yuan Yuan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-14       Impact factor: 5.555

5.  Effect of Genetic Variants of Gonadotropins and Their Receptors on Ovarian Stimulation Outcomes: A Delphi Consensus.

Authors:  Alessandro Conforti; Frank Tüttelmann; Carlo Alviggi; Hermann M Behre; Robert Fischer; Liang Hu; Nikolaos P Polyzos; Dana Chuderland; Gottumukkala Achyuta Rama Raju; Thomas D'Hooghe; Manuela Simoni; Sesh K Sunkara; Salvatore Longobardi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-01       Impact factor: 5.555

6.  FSH Requirements for Follicle Growth During Controlled Ovarian Stimulation.

Authors:  Ali Abbara; Aaran Patel; Tia Hunjan; Sophie A Clarke; Germaine Chia; Pei Chia Eng; Maria Phylactou; Alexander N Comninos; Stuart Lavery; Geoffrey H Trew; Rehan Salim; Raj S Rai; Tom W Kelsey; Waljit S Dhillo
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-27       Impact factor: 5.555

7.  POSEIDON classification and the proposed treatment options for groups 1 and 2: time to revisit? A retrospective analysis of 1425 ART cycles.

Authors:  Parimala Chinta; Belavendra Antonisamy; Ann M Mangalaraj; Aleyamma T Kunjummen; Mohan S Kamath
Journal:  Hum Reprod Open       Date:  2021-02-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.